Clinical Trial

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Study acronym: DO-01
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry \[IHC\] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
Protocol Amendment History 3 changes
notable Trial sites expanded: 205 -> 208 locations 2026-07-03
notable Trial sites expanded: 193 -> 205 locations 2026-06-23
notable Trial sites expanded: 180 -> 193 locations 2026-05-27
Trial Details
NCT Number NCT06819007
Lead Sponsor Daiichi Sankyo
Conditions Ovarian Cancer
Enrollment 582 participants
Start Date 2025-03-19
Primary Completion 2028-11-01 (estimated)
Study Completion 2032-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-02